TY - JOUR
T1 - Galectin-3 and venous thromboembolism incidence
T2 - the Atherosclerosis Risk in Communities (ARIC) Study
AU - Fashanu, Oluwaseun E.
AU - Heckbert, Susan R.
AU - Aguilar, David
AU - Jensen, Paul N.
AU - Ballantyne, Christie M.
AU - Basu, Saonli
AU - Hoogeveen, Ron C.
AU - deFilippi, Christopher
AU - Cushman, Mary
AU - Folsom, Aaron R.
N1 - Publisher Copyright:
© 2017 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis.
PY - 2017/10
Y1 - 2017/10
N2 - Essentials Galectin-3, an inflammatory biomarker, is involved in murine thrombogenesis. Galectin-3–binding protein is up-regulated in microparticles from deep venous thrombosis patients compared to control patients. In this prospective epidemiological study, participants with plasma galectin-3 concentrations in the highest quintile had a greater risk of incident venous thromboembolism than did those in the lowest quintile. The association of galectin-3 and VTE was not replicated in a second prospective study, but the meta-analyzed hazard ratio still indicated a positive association. Galectin-3 is associated positively with risk of venous thromboembolism. Background: The inflammatory biomarker galectin-3 contributes to pathologic conditions such as heart failure and stimulates murine thrombogenesis. Its association with venous thromboembolism (VTE) has been sparsely studied. Objectives: To assess the prospective association of plasma galectin-3 and the LGALS3 rs4644 SNP with VTE incidence. Methods: We measured plasma galectin-3 in 9916 participants in the Atherosclerosis Risk in Communities (ARIC) study cohort in 1996-1998 and identified VTEs through 2013. Using Cox regression, we estimated the hazard ratio associating galectin-3 with incident VTE over a median of 13.9 years. Replication was sought in the Cardiovascular Health Study (CHS). Results: ARIC included 21.8% blacks and 56.2% females with mean baseline age of 62.7 years. The incidence rate of VTE (n=389 events) increased across quintiles of galectin-3, with hazard ratios (95% CI) of 1 (reference), 1.13 (0.80-1.61), 1.00 (0.70-1.43), 1.36 (0.96-1.91), and 1.55 (1.09-2.19) (P-trend=.005), adjusted for age, sex, race, body mass index, diabetes status, and renal function. Results did not replicate in the CHS (124 VTE), but meta-analysis of both studies yielded a pooled hazard ratio (95% CI) for 1 SD increment in log galectin-3 of 1.10 (1.00-1.22). In ARIC, the C allele of rs4644 in the LGALS3 gene was associated with higher galectin-3 level, and in whites, with an increased rate of VTE. Conclusion: Galectin-3 levels were associated positively with VTE incidence.
AB - Essentials Galectin-3, an inflammatory biomarker, is involved in murine thrombogenesis. Galectin-3–binding protein is up-regulated in microparticles from deep venous thrombosis patients compared to control patients. In this prospective epidemiological study, participants with plasma galectin-3 concentrations in the highest quintile had a greater risk of incident venous thromboembolism than did those in the lowest quintile. The association of galectin-3 and VTE was not replicated in a second prospective study, but the meta-analyzed hazard ratio still indicated a positive association. Galectin-3 is associated positively with risk of venous thromboembolism. Background: The inflammatory biomarker galectin-3 contributes to pathologic conditions such as heart failure and stimulates murine thrombogenesis. Its association with venous thromboembolism (VTE) has been sparsely studied. Objectives: To assess the prospective association of plasma galectin-3 and the LGALS3 rs4644 SNP with VTE incidence. Methods: We measured plasma galectin-3 in 9916 participants in the Atherosclerosis Risk in Communities (ARIC) study cohort in 1996-1998 and identified VTEs through 2013. Using Cox regression, we estimated the hazard ratio associating galectin-3 with incident VTE over a median of 13.9 years. Replication was sought in the Cardiovascular Health Study (CHS). Results: ARIC included 21.8% blacks and 56.2% females with mean baseline age of 62.7 years. The incidence rate of VTE (n=389 events) increased across quintiles of galectin-3, with hazard ratios (95% CI) of 1 (reference), 1.13 (0.80-1.61), 1.00 (0.70-1.43), 1.36 (0.96-1.91), and 1.55 (1.09-2.19) (P-trend=.005), adjusted for age, sex, race, body mass index, diabetes status, and renal function. Results did not replicate in the CHS (124 VTE), but meta-analysis of both studies yielded a pooled hazard ratio (95% CI) for 1 SD increment in log galectin-3 of 1.10 (1.00-1.22). In ARIC, the C allele of rs4644 in the LGALS3 gene was associated with higher galectin-3 level, and in whites, with an increased rate of VTE. Conclusion: Galectin-3 levels were associated positively with VTE incidence.
KW - Galectin-3
KW - gene
KW - prospective
KW - thrombosis
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85052406836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052406836&partnerID=8YFLogxK
U2 - 10.1002/rth2.12038
DO - 10.1002/rth2.12038
M3 - Article
AN - SCOPUS:85052406836
SN - 2475-0379
VL - 1
SP - 223
EP - 230
JO - Research and Practice in Thrombosis and Haemostasis
JF - Research and Practice in Thrombosis and Haemostasis
IS - 2
ER -
